Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01360021 · ClinicalTrials.gov registry record · Phase 3
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT01360021 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 214 participants.
The verdict
NCT01360021, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
Interventions
- DRUG Budesonide
- DRUG Symbicort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01360021
The ClinicalTrials.gov registry entry for NCT01360021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Budesonide is the first listed.
NCT01360021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01360021 about?
NCT01360021 is a clinical study titled "New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day". This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
What is the current status of trial NCT01360021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2011-11. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01360021?
The interventions under investigation include: Budesonide (DRUG), Symbicort (DRUG).
Who is sponsoring clinical trial NCT01360021?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.